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Abstract
Chronic inﬂammation and proatherogenic lipids are important risk factors of cardiovascular disease (CVD). Speciﬁc dietary
constituents such as polyphenols and ﬁsh oils may improve cardiovascular risk factors and may have a beneﬁcial effect on
disease outcomes. We hypothesized that the intake of an antiinﬂammatory dietary mixture (AIDM) containing resveratrol,
lycopene, catechin, vitamins E and C, and ﬁsh oil would reduce inﬂammatory risk factors, proatherogenic lipids, and
endpoint atherosclerosis. AIDM was evaluated in an inﬂammation model, male human C-reactive protein (CRP) transgenic
mice, and an atherosclerosis model, female ApoE*3Leiden transgenic mice. Two groups of male human-CRP transgenic
mice were fed AIDM [0.567% (wt:wt) powder and 0.933% (wt:wt oil)] or placebo for 6 wk. The effects of AIDM on basal
and IL-1b–stimulated CRP expression were investigated. AIDM reduced cytokine-induced human CRP and ﬁbrinogen
expression in human-CRP transgenic mice. In the atherosclerosis study, 2 groups of female ApoE*3Leiden transgenic
mice were fed an atherogenic diet supplemented with AIDM [0.567% (wt:wt) powder and 0.933% (wt:wt oil)] or placebo
for 16 wk. AIDM strongly reduced plasma cholesterol, TG, and serum amyloid A concentrations compared with placebo.
Importantly, long-term treatment of ApoE*3Leiden mice with AIDM markedly reduced the development of atheroscle-
rosis by96% comparedwithplacebo.The effecton atherosclerosis was paralleledbya reducedexpressionof thevascular
inﬂammation markers and adhesion molecules inter-cellular adhesion molecule-1 and E-selectin. Dietary supplementation
of AIDM improves lipid and inﬂammatory risk factors of CVD and strongly reduces atherosclerotic lesion development in
female transgenic mice. J. Nutr. 141: 863–869, 2011.
Introduction
Cardiovascular disease (CVD)
7 remains the leading cause of
morbidity and mortality in the Western world. A sedentary
lifestyle and Western dietary habits can contribute to an increased
risk of developing CVD (1,2). For example, the consumption of
diets rich in saturated fat is positively associated with elevated
plasma lipid levels and a state of subacute chronic inﬂammation,
which are 2 important risk factors promoting the onset and
development of CVD (3,4). More speciﬁcally, LDL-cholesterol,
TG, and the inﬂammatory molecules C-reactive protein (CRP),
serum amyloid A (SAA), E-selectin, and inter-cellular adhesion
molecule-1 (ICAM-1) are risk factors implicated in the processes
leading to atherosclerosis and the occurrence of cardiovascular
events (5–7).
An effective way to diminish the risk of CVD is to reduce
causative risk factors. Improvement of lifestyle and dietary
habits helps to reduce some of the risk factors, although the
absolute effectiveness of lifestyle interventions remains ques-
tionable (8), the more so because long-lasting adjustments of
lifestyle habits have proven to be difﬁcult to implement (9).
Supplementation of diets with speciﬁc protective components
may be an attractive and more feasible alternative to diminish
CVD. A number of dietary compounds have been associated
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studies suggest a beneﬁcial effect on the cardiovascular event rate
in humans (10–13). For example, dietary supplementation of lyco-
p e n e( 6 0m g / d )t om e nf o ra3 - m op e r i o dr e s u l t e di nas i g n i ﬁ c a n t
14% reduction of LDL-cholesterol (12). Increased consumption
of green tea extracts rich in catechins was associated with
decreased plasma cholesterol and TG (10). Also, polyphenols
such as resveratrol can promote vasorelaxation and thereby
protect the human endothelium (11). In addition, a recent meta-
analysis showed that increased consumption of the PUFA, EPA
and DHA, is linked to a reduction of plasma lipids, inﬂamma-
tory mediators, and soluble adhesion molecules (13). Collec-
tively, these studies demonstrate that intake of speciﬁc dietary
components may reduce proatherogenic lipids and inﬂammatory
risk factors participating in disease, suggesting that a combina-
tion of several of these beneﬁcial components into a mixture may
be an effective strategy for disease prevention.
Recently, we tested such a mixture containing ﬁsh oil, res-
veratrol, lycopene, catechin, d-a-tocopherol, and vitamin C
[antiinﬂammatory dietary mixture (AIDM)] in healthy but
overweight volunteers (14). Five weeks of AIDM treatment had
a positive effect on factors implicated in inﬂammation, oxidative
stress, and dyslipidemia. Here we tested AIDM at a concentra-
tion equivalent to the dose used in the human trial in “human-
ized”: animal models (15–17) of inﬂammation (human-CRP
transgenic mice) and atherosclerosis (ApoE*3Leiden transgenic
mice) to investigate putatively beneﬁcial effects of AIDM on
inﬂammatory risk factors and cardiovascular endpoints.
Methods
Mice
Animal experiments conformed to the regulations set forward by the
Netherlands Law on Animal Experiments and the Institutional Animal Care
and Use Committee of TNO. Mice consumed diets and water ad libitum.
All mice used are on a C57BL/6 background. Male human-CRP
transgenic mice (TNO-Pharma, Gaubius Laboratory) carry a 31-kb human
DNA fragment containing the human CRP gene, including all known cis-
acting regulatory elements, i.e. the entire human CRP promoter, and show a
human-like pattern of expression (18). Male mice were used because their
baseline CRP level in plasma is sufﬁciently high to be detected by ELISA,
whereas this is not the case in females. ApoE*3Leiden transgenic mice (TNO-
Pharma, Gaubius Laboratory) were characterized for expression of human
ApoE by ELISA (17). Female ApoE*3Leiden mice were used because they are
more prone than their male counterparts to develop atherosclerosis (19).
AIDM
AIDM was recently tested in humans (14) and the same batch was used
herein. AIDM consists of a powder and an oil and the composition is
reportedin(14).Brieﬂy,thepowder(MicrozFoodSupplements)contained
6.3 mg resveratrol, tomato extract containing 3.75 mg lycopene, 94.5 mg
green tea extract (40% epigallocatechin gallate), 90.7 mg d-a-tocopherol,
and 125 mg vitamin C. The oil contained 1200 mg ﬁsh oil (380 mg EPA,
260 mg DHA, and 60 mg other PUFA) (Omega-3–700, Solgar Vitamin
and Herb). The powder and oil were mixed into a nonpuriﬁed diet (CRP
study) or an atherogenic diet (ApoE*3Leiden studies). The placebo con-
tained 365 mg microcrystalline cellulose (Microz Food Supplements) and
1.36 g soy lecithin (soya lecithin; Solgar Vitamin and Herb) and was also
mixed into the diets.
CRP study
Two groups of male human-CRP transgenic mice (n = 7/group) were fed
a standard nonpuriﬁed diet [Ssniff R/M-H Chow Diet, Spezialdia ¨ten;
crude nutrients (in g/kg dry matter): protein, 216; N-free extract,
617; fat, 38; ﬁber, 56; ash, 73; supplemented with vitamins and minerals;
16.0 MJ/kg metabolizable energy]. One group received AIDM [0.567%
(wt:wt) powder and 0.933% (wt:wt) oil] that was mixed into the
nonpuriﬁed diet. The dose of AIDM used for the CRP study was equal to
the highest dose used in ApoE*3Leiden mice (see below). The other
group received a similar amount of placebo, which was composed as
speciﬁed above. After 6 wk of treatment, mice were stimulated with an
i.p. injection of 125k IU IL-1b (Sanvertech). IL-1b induces CRP
expression with maximal effect 18 h after the injection (15). Tail blood
samples were collected before and 18 h after IL-1b injection with EDTA
as an anticoagulant.
Determination of dose and atherosclerosis studies
Dose determination study. During a run-in period of 3 wk,
ApoE*3Leiden mice (12 wk old; n = 14/group) were fed a 0.5% (wt:wt)
cholesterol-containing, atherogenic, high-cholesterol diet (referred to as
the HC diet; Hope Farms). This HC diet is a well-established diet to
induce atherosclerosis (for diet composition, see Supplemental Table 1)
containing (all wt:wt) 15% cacao butter, 1% corn oil, 40.5% sucrose,
20% acid casein, 10% corn starch, 5.7% cellulose, and 0.5% cholesterol
(17). Mice were matched into 2 groups based on plasma cholesterol
levels. One group received increasing doses of AIDM mixed into the HC
diet: from wk 0 to 2, low dose [0.063% (wt:wt) powder and 0.104%
(wt:wt) oil]; from wk 2 to 4, medium dose [0.189% (wt:wt) powder and
0.311% (wt:wt) oil]; and from wk 4 to 6, high dose [0.567% (wt:wt)
powderand 0.933%(wt:wt)oil]. Theothergroup consumed the HC diet
containing increasing doses of placebo. Blood samples were taken at the
start and end of each dosing period.
Atherosclerosis study. During a run-in period of 3 wk, 30 female E3L
mice received the HC diet. Then, mice were matched into 2 groups based
on plasma cholesterol and TG concentrations. One group was treated for
16 wk with HC containing the high-dose AIDM (AIDM group). The
placebo groupconsumedthe HCcontainingthe same dose ofplacebo.Tail
blood sampleswere collectedat 0, 2,4, 8,12,and16wk. Mice were killed
by carbon dioxide inhalation and hearts with aortic roots were collected.
Analysis of plasma lipids, lipoproteins,
and inﬂammation markers
Plasma total cholesterol and TG concentrations were measured in blood
samples collected into EDTA-tubes from mice after 4 h of food dep-
rivation [kit nos. 11489437 and 11488872, Roche Diagnostics, respec-
tively (20)]. For lipoprotein proﬁles, pooled plasma obtained during wk
16 was fractionated using an AKTA FPLC system (Pharmacia) (21). The
plasma levels of SAA were determined by ELISA (Tridelta; catalog no.
TP802-M) and ﬁbrinogen was quantiﬁed with an in-house ELISA (22).
E-selectin and ICAM-1 were quantiﬁed by established ELISA (R&D
Systems Europe).
Atherosclerotic lesion analysis
Hearts were ﬁxed and embedded in parafﬁn to prepare serial cross-
sections(5mmthick)throughout theentire aorticrootarea for(immuno)
histological analysis (16). Cross-sections were stained with hematoxylin-
phloxine-saffron and atherosclerosis was analyzed without knowledge
of treatment groups. Due to a technical problem, 1 heart from the
placebo group was lost. For immunostaining of ICAM-1, antibody
GTX76543 from GeneTex, Biotechnology was used.
Statistical methods
Data in the CRP study were analyzed by 2-way ANOVA (CRP study:
AIDM 3 IL-1b;d o s es t u d y :t r e a t m e n t3 dose) or repeated-measures
ANOVA (atherosclerosis study). When appropriate, data were then
subject to the least signiﬁcant difference post hoc test. Based on Levene’s
test forequalvariances, the nonparametricMann-WhitneyUtest was used
to analyze the SAA data in the atherosclerosis study. Inall tests performed,
the null hypothesis was rejected at the level of 5% probability (a =0 . 0 5 ) .
Results
AIDM reduces CRP expression in male human-CRP trans-
genic mice. At the start, the body weight of the placebo (31.4 6
2.4 g) and AIDM groups (32.0 6 2.7 g) did not differ nor did
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respectively). AIDM also did not signiﬁcantly affect daily food
intake, which was 3.6 6 0.5 g/d in the placebo group and 3.3 6
0.1 g/d in the AIDM group.
The placebo and AIDM groups had comparable baseline
CRP concentrations of 7.3 6 3.4 and AIDM 6.4 6 1.8 mg/L,
respectively, which did not change in either group and were 7.1 6
2.1 and 5.9 6 2.1 mg/L, respectively, at the end of the study.
The i.p. injection of IL-1b resulted in a signiﬁcant 3-fold
stimulation of CRP (Fig. 1A) in the placebo group. In the AIDM
group, CRP levels also increased signiﬁcantly after IL-1b injection.
However, compared with placebo-treated mice, the inﬂammatory
response of AIDM-treated mice was signiﬁcantly quenched. Fi-
brinogen, another hepatic inﬂammation marker, had a similar
response to CRP (Fig. 1B). At the start, plasma ﬁbrinogen levels
were comparable in the placebo group (2.2 6 0.7 g/L) and the
AIDM group (2.3 60.9 g/L). The ﬁbrinogen concentration did not
change over time in either group (data not shown). Stimulation
with IL-1b signiﬁcantly increased ﬁbrinogen expression in the
placebo group and AIDM fully quenched this effect (Fig. 1B).
Furthermore, AIDM reduced plasma TG concentrations from
1.2 6 0.4 to 0.7 6 0.2 mmol/L, whereas there was no change
in the placebo group with concentrations of 1.3 6 0.5 and 1.0 6
0.3 mmol/L at the beginning and end of the study, respectively.
Dose determination study with AIDM in female ApoE*3-
Leiden mice. To deﬁne the AIDM dose that was needed to
affect cardiovascular risk factors under atherogenic conditions,
a dose-ﬁnding study in ApoE*3Leiden mice was performed. At
the start of the intervention, the plasma cholesterol concentra-
tion did not differ between the placebo (16.3 6 2.0 mmol/L) and
AIDM (16.4 6 3.7 mmol/L) groups. With increasing dietary
concentrations of AIMD (switch to higher dose every 2 wk),
plasma cholesterol levels decreased signiﬁcantly and dose
dependently. The maximal plasma cholesterol-lowering effect
was achieved with the highest dose of AIDM (44% reduction;
9.1 6 1.3 mmol/L). The placebo treatment did not affect the
plasma cholesterol concentrations. AIDM treatment also dose-
dependently decreased plasma TG concentrations from 2.5 6
0.7 mmol/L at baseline to 0.8 6 0.2 mmol/L at the end of the
study (P , 0.001). The concentration in the group given the high
dose of AIDM was 48% lower than in the placebo group. The
plasma TG concentration also decreased in the placebo group
from 2.6 6 0.6 mmol/L to 1.5 6 0.2 mmol/L (P , 0.05), but the
effect was less pronounced than in the AIDM-treated group.
To test a possible antiinﬂammatory effect of AIDM, we
measured the plasma concentration of SAA, a systemic inﬂam-
mation marker. At the start of the intervention, SAA did not
differ between the placebo (8.4 6 1.8 mg/L) and AIDM (7.0 6
2.3 mg/L) groups. The low and medium doses of AIDM did not
affect the SAA concentration. However, the high dose of AIDM
resulted in a plasma SAA concentration (3.6 6 1.7 mg/L) that
was lower than in the placebo group (8.9 6 4.0 mg/L; P , 0.01).
Therefore, the high dose of AIMD was used in a subsequent
long-term intervention study.
AIDM treatment attenuates the development of athero-
sclerosis. During the atherosclerosis study, the gain in body
weight in the AIDM group (4.5 6 2.1 g) was greater in the
placebo group (2.0 6 0.9 g; P , 0.01). This effect was paralleled
by a greater daily food intake in the AIDM group (2.6 6 0.1 g/d)
than in the placebo group (2.3 6 0.2 g/d; P , 0.05).
Baseline plasma cholesterol levels were comparable between
the placebo group (15.6 6 2.1 mmol/L) and the AIDM group
(15.4 6 3.2 mmol/L). While cholesterol levels did not change
over time in the placebo group. AIDM rapidly (within 2 wk) and
signiﬁcantly decreased plasma cholesterol levels by 43% com-
pared with the start of the study (Fig. 2A). Plasma TG con-
centrations were signiﬁcantly reduced within 2 wk by 41% in
the AIDM group compared with baseline and did not change
over time in the placebo group (Fig. 2B). The TG-lowering effect
of AIDM persisted until the end of the study. Analysis of lipo-
protein proﬁles for cholesterol demonstrated that AIDM markedly
reduced cholesterol in the proatherogenic apoB-containing lipo-
proteins VLDL and LDL (Fig. 2C).
To evaluate whether AIDM exerted antiinﬂammatory activity
during atherogenesis, plasma SAA concentrations were analyzed.
Atthe startof the study, plasma SAA concentrations did notdiffer
between the groups (Fig. 2D). They decreased 40% in the AIDM
group within 2 wk and this persisted until the end of the study.
Plasma SAA concentrations in the placebo group did not change.
The placebo group developed atherosclerosis (total lesion area
of 59,700 6 11,000 mm
2), whereas AIDM treatment strongly
reduced atherosclerosis development (P , 0.001; Fig. 3A,B).
Placebo-treated mice had 6.8 6 2.5 lesions/mouse and AIDM
treatment reduced the lesion number by 92% (Fig. 3C; P ,
0.001). These data indicate that AIDM strongly inhibits athero-
genesis and suggest that AIDM interferes in processes critical for
early lesion formation.
Monocyte adhesion is one of the early events in atheroscle-
rotic lesion development. This process is mediated through cellular
FIGURE 1 Plasma human CRP (A) and fibrinogen (B) concentrations
in male human-CRP transgenic mice fed placebo or AIDM for 6 wk and
before and after IL-1b stimulation. Values are mean 6 SD, n =7 .
Within a diet group, means without a common letter differ, P , 0.05.
*Different from corresponding placebo, P , 0.05.
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histochemical staining of the vasculature showed that mice in
the AIDM group expressed less ICAM-1 on endothelial cells
compared with mice in the placebo group (Fig. 4A). Subsequent
quantiﬁcation of ICAM-1 immunoreactivity showed that 69 6
13% of the endothelial cells of the placebo group expressed
ICAM-1 and that the percentage of ICAM-1–positive endothe-
lial cells in the AIDM group was reduced (P , 0.01; Fig. 4B).
Because the observed difference in ICAM-1 might reﬂect the
difference in atherosclerosis, we measured plasma adhesion
molecule E-selectin concentrations.
The placebo group and the AIDM group had comparable
baseline plasma E-selectin concentrations (Fig. 4C). Compared
with baseline (t0), AIDM treatment signiﬁcantly reduced E-selectin
levels within 2 wk, demonstrating that AIDM has a rapid anti-
inﬂammatory effect on the vasculature. E-selectin concentra-
tions of AIDM-treated mice remained signiﬁcantly lower than
those of the placebo-treated mice at the end of the study.
Discussion
The diets and eating habits in modern societies are associated
with unfavorable effects on risk factors of CVD, e.g. increased
circulating levels of atherogenic lipids (VLDL/LDL-cholesterol
and TG) and inﬂammation markers such as CRP, SAA, ﬁbrinogen,
E-selectin, and ICAM-1. Because of the complex and multi-
factorial nature of the atherosclerotic disease process, we hypo-
thesized that a mixture of putative beneﬁcial dietary components
would simultaneously act on multiple risk factors and thereby may
constitute an effective nutrition-based strategy for preventing CVD.
We demonstrate here that a mixture containing ﬁsh oil, res-
veratrol, lycopene, catechin, d-a-tocopherol, and vitamin C
(AIDM) reduces lipid and inﬂammatory risk factors of CVD and
that long-term AIDM treatment strongly attenuates the devel-
opment of atherosclerosis by inhibiting early processes crucial
for disease initiation.
To investigate the health effects of AIDM, we used 2 trans-
genic mouse models, human-CRP transgenic mice and human
ApoE*3Leiden transgenic mice. The background of these mice is
C57BL/6, but the mice carry the human transgenes, including
respective human regulatory elements. Because mouse-CRP is not
an inﬂammation marker, human-CRP mice allow the investiga-
tion of the effects of an intervention on the expression of CRP,
one of the most sensitive human inﬂammation markers and a
FIGURE 2 Plasma cholesterol (A), and TG (B)
concentrations, lipoprotein distribution (C), and SAA
concentrations (D) in female ApoE*3Leiden mice
fed an atherogenic HC diet with placebo or AIDM
for 16 wk. Values are mean 6 SD, n = 15. Within a
diet group, labeled means without a common letter
differ, P , 0.05. *Different from placebo at that
time, P , 0.05.
FIGURE 3 Quantitative analysis (A), representative pictures (B), and
lesion number (C) of atherosclerosis in female ApoE*3Leiden mice fed
an atherogenic HC diet with placebo or AIDM for 16 wk. Values are
mean 6 SD, n = 14 (placebo-treated) and 15 (AIDM-treated mice).
*Different from placebo, P , 0.001.
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The second model, ApoE*3Leiden mice, is an established
atherosclerosis model (17). In contrast to other models of
atherosclerosis (ApoE2/2 and LDLR2/2 mice), ApoE*3Leiden
mice are sensitive to hypolipidemic actives (e.g. statins, ﬁbrates,
ﬁsh oil) and they show a cholesterol-lowering response. Unlike
ApoE2/2 and LDLR2/2 mice, ApoE*Leiden mice are not ge-
netically deﬁcient for components that are necessary to meta-
bolize lipids and to clear apoB-containing lipoproteins from the
circulation. Because of these unique translational characteristics,
human-CRP transgenic mice and ApoE*3Leiden mice are re-
ferred to as humanized mouse models for studying inﬂammation
and atherosclerosis, respectively.
We found that AIDM did not alter human CRP levels in
human-CRP transgenic mice fed a nonpuriﬁed diet (i.e. under a
healthy dietary condition). This observation is consistent with
previous ﬁndings in healthy human volunteers whose baseline
CRP levels were also not affected by AIDM (14). IL-1b and IL-6
are the main inducers of CRP and are also involved in the process
of atherosclerosis (24). AIDM suppressed a mild stimulation of
CRP with IL-1b by ;54%. IL-1b directly activates NF-kBa n d
CCAAT/enhancer binding protein-b (C/EBPb) transcription
factors to stimulate CRP gene expression (15) as well as the
expression of IL-6, which controls STAT3-mediated transcrip-
tion of CRP and another cardiovascular risk factor, ﬁbrinogen,
which is mainly regulated by STAT3 and C/EBPb (15,25). Under
the conditions applied, the IL-1b–stimulated induction of
ﬁbrinogen was fully blocked. This different efﬁcacy of AIDM
in quenching CRP and ﬁbrinogen induction suggests that AIDM
only partly quenches the activation of NF-kB but fully blocks
STAT3 and/or C/EBPb activation. A possible mechanistic ex-
planation for the antiinﬂammatory effect of AIDM might be that
speciﬁc fatty acids that are present in AIDM may activate PPARa,
a potent and global suppressor of the IL-6–mediated acute phase
response (25), which also physically inactivates NF-kB( 2 6 ) .
The activation of PPARa would be consistent with the reduc-
tion of plasma TG seen in both human-CRP transgenic mice and
ApoE*3Leiden transgenic mice. Activation of PPARa increases
b-oxidation of fatty acids, resulting in a marked TG-lowering
effect. A recent study in dyslipidemic volunteers treated with a
supplement of ﬁsh oils and vitamin E reported cholesterol- and
TG-lowering as well as antiinﬂammatory effects, which is in line
with the observations made herein (27).
It was documented that epigallocatechin gallate in green tea
extract, lycopene from tomato extract, and a-tocopherol can
reduce NF-kB activation (28–30). Because AIDM contains all of
these active compounds, this may possibly explain the reduced
expression of NF-kB–regulated factors (e.g. CRP, SAA, and
E-selectin) in AIDM-treated mice.
In a previous study (31), we found that feeding ApoE*3Leiden
transgenic mice an atherogenic diet activates speciﬁc signaling
pathways (IL-1, TNFa, PDGF, IFNg)t h a tl e a dt oN F - kB,
C/EBPb, and STAT3 activation and that these inﬂammatory
pathways are not activated in ApoE*3Leiden transgenic mice
fed a nonpuriﬁed diet. Consistent with this, AIMD reduced the
inﬂammatory state under experimental conditions of athero-
sclerosis (atherogenic diet feeding of ApoE*3Leiden mice) and
cytokine-induced inﬂammation (IL-1b stimulated human-CRP
transgenic mice) but did not have an effect on baseline CRP
levels of unstimulated mice fed a nonpuriﬁed diet.
We found that AIDM treatment markedly reduced plasma
TGlevels withina fewweeks.ComparableTG-lowering effects
were found in humans treated with AIDM (14). In humans,
AIDM had no plasma LDL cholesterol-lowering effect, whereas
in ApoE*3Leiden mice, plasma cholesterol conﬁned to VLDL
and LDL was strongly reduced. This apparent discrepancy may
be due to a different health state; ApoE*3Leiden mice received
an atherogenic diet to establish a condition of dyslipidemia
(increased VLDL and LDL cholesterol), whereas human vol-
unteers were healthy individuals with normal plasma choles-
terol levels that possibly could not be further lowered with
AIDM.
Analysis of atherosclerotic lesions revealed that AIDM-
treated mice developed markedly fewer lesions than placebo-
treated controls. This indicates that AIDM interferes with
processes relevant for lesion initiation and that it protects
against onset of the disease. The recruitment of inﬂammatory
cells from the circulation and their inﬁltration into the vascu-
lature is an important early stage process and is predominantly
mediated by adhesion molecules such as E-selectin and ICAM-1,
which are expressed on the endothelial surface. Indeed, AIDM
diminished endothelial ICAM-1 expression in the aortic root
and plasma E-selectin levels were signiﬁcantly reduced with
AIDM. In previous studies, reduced vascular inﬂammation and
improved endothelial function were achieved with resveratrol
(32), lycopene (33), green tea catechins (28), and vitamin E (34),
all of which are present in AIDM. The 2 vitamins in AIDM, E
and C, can affect various metabolic pathways and diminish the
oxidation of circulating lipids and thereby contribute to the
antiatherogenic effect observed (35,36). Because AIDM reduced
vascular inﬂammation already at an early time point, i.e. before
atherosclerosis became manifest, the effect of AIDM can be
viewed as directly atheroprotective.
FIGURE 4 Representative pictures (A) and quantitative analysis
of ICAM-1 (B) and plasma analysis of E-selectin (C) in female
ApoE*3Leiden mice fed an atherogenic HC diet placebo or AIDM
for 16 wk. Values are mean 6 SD, n = 14 (placebo-treated mice) and
15 (AIDM-treated mice). Within a diet group, means without a
common letter differ, P , 0.05. *Different from placebo at that time,
P , 0.05.
Dietary mix reduces cardiovascular risk in mice 867AIDM had a remarkably strong effect on atherosclerosis that
exceeds the effect of many pharmaceuticals tested in ApoE*3
Leiden mice under comparable experimental conditions (17).
The potency of AIDM may be due to the simultaneous action of
its constituents (and metabolites) on multiple targets, including
plasma lipids (hepatic lipid metabolism), hepatic inﬂammation
(SAA, CRP, and ﬁbrinogen), and vascular inﬂammation (E-selectin,
ICAM). Such broad effects are typically not seen with single
nutrients (37,38). Our ﬁndings support the concept of combina-
tion strategies with several bioactive nutrients and a systems-
based, multi-target approach for complex multifactorial diseases,
such as type 2 diabetes.
Our study demonstrates that a dietary mix of ﬁsh oil, resver-
atrol, lycopene, catechin, d-a-tocopherol, and vitamin C (AIDM)
that was shown to be well tolerated in humans improves lipid and
inﬂammatory risk factors of CVD in humanized models of disease.
Most importantly, long-term treatment with AIDM strongly re-
duces disease endpoints, i.e. atherosclerotic lesion load and lesion
number, further underlining its beneﬁt for disease prevention.
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